Madeleine Johnson

Despite some stumbles by firms that it supported, RADx may serve as a template for other federally funded programs for diagnostics development moving forward.

Despite a few less successful elements, the overall portfolio increased test availability and RADx is now becoming a model for federal investing.

The firm saw growth in its base life science business offset by a decline in COVID-only testing revenues.

On a call with investors to discuss third quarter results, the firm also offered updates on its syndromic testing and NeuMoDx businesses.

The laboratory-developed tests can be validated and customized by customers, which the firm says engenders increased flexibility.

The firm also said it will shift its near-term regulatory and commercial strategy for its Savanna molecular diagnostic instrument.

On a quarterly earnings call, company execs said they expect a significant order backlog due to electronic component supply to lift in Q4.

The firm plans to use the method to develop and commercialize assays for infectious diseases including sexually transmitted infections.

With benefits of new legislation some ways out, developers continue to find workarounds to the lack of reliable microprocessor supplies.

In a report released on Wednesday, the office critiqued the FDA's pandemic performance and recommended new approaches.